Drug Type siRNA |
Synonyms LDR-1259 |
Target |
Action inhibitors |
Mechanism LPA inhibitors(Lysophosphatidic acid inhibitors), PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hyperlipidemias | Phase 1 | China | 24 Aug 2026 |





